Immuno-positron emission tomography (immunoPET) is a paradigm-shifting molecular
imaging modality combining the superior targeting specificity of monoclonal antibody (mAb) …

Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are two interrelated
inflammatory diseases affecting patients above 50 years of age. Patients with GCA suffer …

The past two decades have brought impressive advancements in immune modulation,
particularly with the advent of both cancer immunotherapy and biologic therapeutics for …

Despite the remarkable clinical successes of immune checkpoint inhibitors (ICIs) in various
advanced cancers, response is still limited to a subset of patients that generally exhibit …

B-cell non-Hodgkin lymphoma (B-NHL) is a group of heterogeneous disease which remains
incurable despite developments of standard chemotherapy regimens and new therapeutic …

Programmed death ligand 1 (PD-L1) expression level is a reproducible biomarker for
guiding stratification of patients to immunotherapy. However, the most widely used …

Dramatic, but uneven, progress in the development of immunotherapies for cancer has
created a need for better diagnostic technologies including innovative non-invasive imaging …

Pancreatic ductal adenocarcinoma (PDAC), a deadly cancer characterized by multiple
molecular alterations, remains the most lethal cancer, with a 5‐year survival rate of about 3 …

Radiolabeled antibodies have become indispensable tools in nuclear medicine. However,
the natural roles of antibodies within the immune system mean that they have several …

The concept of positron emission tomography (PET) based imaging was developed more
than 40 years ago. It has been a widely adopted technique for detecting and staging …